Scott McPhee - Concepedia

Author

Scott McPhee

University of North Carolina at Chapel Hill

Also Known As

Albright, Blake, Li, Chengwen, McPhee, Scott, S McPhee, S W J McPhee, S. W. J. McPhee, S. W. McPhee, S.W.J. McPhee, Samulski, R Jude, Santos-Gallego, Carlos G

Publications

Citations

H-Index

Concepts

All Affiliations

University of North Carolina at Chapel Hill AskBio (United States)Johnson University University of Pennsylvania Children's Hospital of Philadelphia

About

Scott McPhee is an author at University of North Carolina at Chapel Hill specializing in medicine, immunology, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	1.5K
2	Biomedical Engineering	2	2	411
3	Cell Biology	2	2	903
4	Engineering	1	1	390
5	Biochemistry	1	1	12

Scott McPhee

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Dystrophin Immunity in Duchenne's Muscular Dystrophy Jerry R. Mendell, Katherine Campbell, Louise R. Rodino‐Klapac, New England Journal of Medicine Autoimmune DiseaseSkeletal MuscleTransgene ExpressionImmunologyPathology	2010	650
Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector Dawn E. Bowles, Scott McPhee, Chengwen Li, Molecular Therapy EngineeringIn Vivo Gene TherapyImmunologyMolecular BiologyBiomedical Engineering	2011	390
Long-Term Follow-Up After Gene Therapy for Canavan Disease Paola Leone, David Shera, Scott McPhee, Science Translational Medicine	2012	322
Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle Aravind Asokan, Julia C Conway, Jana L. Phillips, Nature Biotechnology Viral ReplicationSignal TransductionGene ExpressionVirologyVirus Gene	2009	253
Gene Therapy of Canavan Disease: AAV-2 Vector for Neurosurgical Delivery of Aspartoacylase Gene ( <i>ASPA</i> ) to the Human Brain Christopher G. Janson, Scott McPhee, Larissa T. Bilaniuk, Human Gene Therapy	2002	251
Immune responses to AAV in a phase I study for Canavan disease Scott McPhee, C. G. Janson, Chuang Li, The Journal of Gene Medicine	2006	234
Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease Paola Leone, C. G. Janson, L. Bilianuk, Annals of Neurology	2000	177
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression Barbara A. Konkle, Christopher Walsh, Miguel A. Escobar, Blood	2020	173
Employing a Gain-of-Function Factor IX Variant R338L to Advance the Efficacy and Safety of Hemophilia B Human Gene Therapy: Preclinical Evaluation Supporting an Ongoing Adeno-Associated Virus Clinical Trial Paul E. Monahan, Junjiang Sun, Tong Gui, Human Gene Therapy ImmunologyPathologyEmpty Aav ParticlesImmunotherapyEmpty Aav Capsids	2014	107
Cardiac I-1c Overexpression With Reengineered AAV Improves Cardiac Function in Swine Ischemic Heart Failure Kiyotake Ishikawa, Kenneth Fish, Lisa Tilemann, Molecular Therapy	2014	82

Page 1